FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945750026> ?p ?o ?g. }

• W2945750026 endingPage "867" @default.
• W2945750026 startingPage "867" @default.
• W2945750026 abstract "<h3>Importance</h3> Many cervical cancer screening strategies are now recommended in the United States, but the benefits, harms, and costs of each option are unclear. <h3>Objective</h3> To estimate the cost-effectiveness of 12 cervical cancer screening strategies. <h3>Design, Setting, and Participants</h3> The cross-sectional portion of this study enrolled a convenience sample of 451 English-speaking or Spanish-speaking women aged 21 to 65 years from September 22, 2014, to June 16, 2016, identified at women's health clinics in San Francisco. In this group, utilities (preferences) were measured for 23 cervical cancer screening–associated health states and were applied to a decision model of type-specific high-risk human papillomavirus (hrHPV)–induced cervical carcinogenesis. Test accuracy estimates were abstracted from systematic reviews. The evaluated strategies were cytologic testing every 3 years for women aged 21 to 65 years with either repeat cytologic testing in 1 year or immediate hrHPV triage for atypical squamous cells of undetermined significance (ASC-US), cytologic testing every 3 years for women age 21 to 29 years followed by cytologic testing plus hrHPV testing (cotesting), or primary hrHPV testing alone for women aged 30 to 65 years. Screening frequency, abnormal test result management, and the age to switch from cytologic testing to hrHPV testing (25 or 30 years) were varied. Analyses were conducted from both the societal and health care sector perspectives. <h3>Main Outcomes and Measures</h3> Utilities for 23 cervical cancer screening–associated health states (cross-sectional study) and quality-adjusted life-years (QALYs) and total costs for each strategy. <h3>Results</h3> Utilities were measured in a sociodemographically diverse group of 451 women (mean [SD] age, 38.2 [10.7] years; 258 nonwhite [57.2%]). Cytologic testing every 3 years with repeat cytologic testing for ASC-US yielded the most lifetime QALYs and conferred more QALYs at higher costs ($2166 per QALY) than the lowest-cost strategy (cytologic testing every 3 years with hrHPV triage of ASC-US). All cytologic testing plus hrHPV testing (cotesting) and primary hrHPV testing strategies provided fewer QALYs at higher costs. Adding indirect costs did not change the conclusions. In sensitivity analyses, hrHPV testing every 5 years with genotyping triage beginning at age 30 years was the lowest-cost strategy when hrHPV test sensitivity was markedly higher than cytologic test sensitivity or when hrHPV test cost was equated to the lowest reported cytologic test cost ($14). <h3>Conclusions and Relevance</h3> Cytologic testing every 3 years for women aged 21 to 29 years with either continued cytologic testing every 3 years or switching to a low-cost hrHPV test every 5 years confers a reasonable balance of benefits, harms, and costs. Comparative modeling is needed to confirm the association of these novel utilities with cost-effectiveness." @default.
• W2945750026 created "2019-05-29" @default.
• W2945750026 creator A5014806552 @default.
• W2945750026 creator A5034360127 @default.
• W2945750026 creator A5040412852 @default.
• W2945750026 creator A5045651535 @default.
• W2945750026 creator A5048457646 @default.
• W2945750026 creator A5048520272 @default.
• W2945750026 creator A5053830276 @default.
• W2945750026 creator A5079949843 @default.
• W2945750026 creator A5080296928 @default.
• W2945750026 creator A5086537473 @default.
• W2945750026 date "2019-07-01" @default.
• W2945750026 modified "2023-10-14" @default.
• W2945750026 title "Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies" @default.
• W2945750026 cites W1537598136 @default.
• W2945750026 cites W1678831856 @default.
• W2945750026 cites W1782204000 @default.
• W2945750026 cites W1948599825 @default.
• W2945750026 cites W1985882656 @default.
• W2945750026 cites W1986701133 @default.
• W2945750026 cites W2020327034 @default.
• W2945750026 cites W2035885645 @default.
• W2945750026 cites W2050056063 @default.
• W2945750026 cites W2064534622 @default.
• W2945750026 cites W2099665607 @default.
• W2945750026 cites W2114418380 @default.
• W2945750026 cites W2128911553 @default.
• W2945750026 cites W2132640627 @default.
• W2945750026 cites W2149198543 @default.
• W2945750026 cites W2155105463 @default.
• W2945750026 cites W2170789578 @default.
• W2945750026 cites W2171104009 @default.
• W2945750026 cites W2174023915 @default.
• W2945750026 cites W2340151363 @default.
• W2945750026 cites W2417221735 @default.
• W2945750026 cites W2463208352 @default.
• W2945750026 cites W2519603001 @default.
• W2945750026 cites W2526320839 @default.
• W2945750026 cites W2569472942 @default.
• W2945750026 cites W2803368909 @default.
• W2945750026 cites W2810057587 @default.
• W2945750026 cites W2883913647 @default.
• W2945750026 cites W2888518378 @default.
• W2945750026 cites W2888613042 @default.
• W2945750026 cites W2909340392 @default.
• W2945750026 cites W3175504568 @default.
• W2945750026 cites W4245702094 @default.
• W2945750026 cites W4245955512 @default.
• W2945750026 cites W4247724132 @default.
• W2945750026 cites W4247795129 @default.
• W2945750026 doi "https://doi.org/10.1001/jamainternmed.2019.0299" @default.
• W2945750026 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6515585" @default.
• W2945750026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31081851" @default.
• W2945750026 hasPublicationYear "2019" @default.
• W2945750026 type Work @default.
• W2945750026 sameAs 2945750026 @default.
• W2945750026 citedByCount "25" @default.
• W2945750026 countsByYear W29457500262019 @default.
• W2945750026 countsByYear W29457500262020 @default.
• W2945750026 countsByYear W29457500262021 @default.
• W2945750026 countsByYear W29457500262022 @default.
• W2945750026 countsByYear W29457500262023 @default.
• W2945750026 crossrefType "journal-article" @default.
• W2945750026 hasAuthorship W2945750026A5014806552 @default.
• W2945750026 hasAuthorship W2945750026A5034360127 @default.
• W2945750026 hasAuthorship W2945750026A5040412852 @default.
• W2945750026 hasAuthorship W2945750026A5045651535 @default.
• W2945750026 hasAuthorship W2945750026A5048457646 @default.
• W2945750026 hasAuthorship W2945750026A5048520272 @default.
• W2945750026 hasAuthorship W2945750026A5053830276 @default.
• W2945750026 hasAuthorship W2945750026A5079949843 @default.
• W2945750026 hasAuthorship W2945750026A5080296928 @default.
• W2945750026 hasAuthorship W2945750026A5086537473 @default.
• W2945750026 hasBestOaLocation W29457500261 @default.
• W2945750026 hasConcept C121608353 @default.
• W2945750026 hasConcept C126322002 @default.
• W2945750026 hasConcept C131872663 @default.
• W2945750026 hasConcept C142052008 @default.
• W2945750026 hasConcept C142724271 @default.
• W2945750026 hasConcept C159110408 @default.
• W2945750026 hasConcept C160735492 @default.
• W2945750026 hasConcept C162324750 @default.
• W2945750026 hasConcept C194828623 @default.
• W2945750026 hasConcept C2777120189 @default.
• W2945750026 hasConcept C2777343196 @default.
• W2945750026 hasConcept C2778220009 @default.
• W2945750026 hasConcept C2779951463 @default.
• W2945750026 hasConcept C29456083 @default.
• W2945750026 hasConcept C50522688 @default.
• W2945750026 hasConcept C512399662 @default.
• W2945750026 hasConcept C71924100 @default.
• W2945750026 hasConceptScore W2945750026C121608353 @default.
• W2945750026 hasConceptScore W2945750026C126322002 @default.
• W2945750026 hasConceptScore W2945750026C131872663 @default.
• W2945750026 hasConceptScore W2945750026C142052008 @default.
• W2945750026 hasConceptScore W2945750026C142724271 @default.
• W2945750026 hasConceptScore W2945750026C159110408 @default.

• next